A-987306 is a potent and orally bioavailable histamine H4 antagonist with Kis of 3.4 nM and 5.8 nM for rat H4 and human H4, respectively. A-987306 exhibits anti-inflammatory activity in a mouse peritonitis model [1].

A-987306 exhibits potency as an antagonist of H4 receptors in human, rat, and mouse models, according to cell-based FLIPR assays [1]. Furthermore, it demonstrates significant selectivity for the human H4 receptor, being 620-fold, >1600-fold, and 162-fold more selective over human H1, H2, and H3 receptors, respectively, in cell-based Ca2+-flux FLIPR assays [1]. However, its selectivity is considerably lower in rat models, with only a 4-fold preference for the rat H4 receptor over the rat H3 receptor, as evidenced in FLIPR assays [1].

A-987306, administered at doses ranging from 98.23 μg/kg to 9.82 mg/kg (i.p.), effectively mitigates scratching behaviors triggered by the histamine H4 agonist clobenpropit, highlighting its potential as an anti-pruritic agent. Additionally, when given orally at a dose of 10 mg/kg, A-987306 demonstrates a modest fractional oral bioavailability (Fpo/iv = 26%) with a pharmacokinetic profile characterized by a half-life of 3.7 hours and peak plasma concentration (Cmax) of 0.30 μM, achieved approximately 1.5 hours post-administration. These findings are supported by pharmacokinetic analysis conducted in a mouse model, utilizing intraperitoneal injection as the mode of administration and measuring key parameters such as bioavailability, half-life, maximum concentration, and time to peak concentration to assess the compound’s systemic exposure and disposition.